Skip to main content
OpenTrials
Completed

NCT Number: NCT06652867

Hypoglycemia Biomarkers to Predict Timing of a Hypoglycemic Event

The study aims to obtain a panel of biomarkers from hypoglycemic diabetic patients with either type 1 or type 2 diabetics and from control patients with type 1 or type 2 diabetes who didn't have hypoglycemia in the last 72 hours.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Royal College of Surgeons in Ireland

Manama, Bahrain

About this study

Primary endpoint is establishing a panel of biomarkers from 100 hypoglycemic diabetic patients with type 1 or type 2 Diabetes during the incidence of hypoglycemia by taking a single blood sample to be analyzed for HbA1c, LDL, HDL, Triglycerides, CRP, CBC and biochemical analysis including liver and kidney function tests. In addition to 5 ml serum sample to be centrifuged and stored in RCSI lab.

Inpatient hypoglycemic patients may also be included in group of hypoglycemia and will be required to have a serial of blood samples taken to be analyzed on the 1st hour, 2nd hour, 3rd hour and 4th hour after the hypoglycemic event.

Secondary endpoint involves recruitment of 100 control Diabetic patients with type 1 or type 2 Diabetes to establish a panel of biomarkers by obtaining a blood sample for the HbA1c, LDL, HDL, Triglycerides, CRP, CBC and biochemical analysis including liver and kidney function tests to include 50 subjects fasting overnight and the other 50 subjects to be non-fasting but without having hypoglycemia at the time of recruitment or in the last 72 hours.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

for diabetes subjects with hypoglycemia

  • Diagnosed of type 2 diabetes or type 1 based on the WHO guidelines Patient's age from 21-75 years old
  • Able to say when the hypo had occurred (free style libre in the outpatient setting, or documented blood glucose less than < 4 mmol/l (<70 mg/dl) as an inpatient

Inclusion criteria

for diabetes subjects without hypoglycemia:

  • Diagnosed of type 2 diabetes or type 1 based on the WHO guidelines
  • Patient's age from 21-75 years old
  • No hypoglycemia or hypoglycemia unawareness.

Exclusion criteria

  • eGFR less than 45 ml/min
  • Liver enzymes 3 folds greater than upper limit
  • Pregnancy
  • Patients on steroids or Atypical Antipsychotics or Cyclosporine/Tacrolimus or other medications that may mask hypoglycemia

Exclusion criteria

for diabetes subjects with hypoglycemia

  • Unable to determine when hypoglycemic event had taken place
  • Hypoglycemic unawareness
  • Severe hypoglycemic event in the last 3 months

Exclusion criteria

for diabetes subjects without hypoglycemia

  • Hypoglycemic event in the preceding week
  • Hypoglycemic unawareness

Treatment and study plan

Primary outcomes

  1. Concentrations of a Panel of Protein Biomarkers in hypoglycemic subjects

    Time frame: 1 day from time of presentation

    a panel of biomarkers is measured from a blood test taken during the incidence of hypoglycemia from type 1 or type 2 Diabetic subject.

Secondary outcomes

  1. Concentrations of a Panel of Protein Biomarkers Reference Ranges from non-hypoglycemic diabetic subjects

    Time frame: 3 days from time of presentation

    a panel of biomarkers is measured from a blood test taken from Diabetic subjects (type 1 or type 2) without having hypoglycemia.

Other outcomes

  1. CBC

    Time frame: 1 day from time of presentation

    Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients

  2. CRP

    Time frame: 1 day from time of presentation

    Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients

  3. LDL

    Time frame: 1 day from time of presentation

    Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients

  4. HDL

    Time frame: 1 day from time of presentation

    Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients

  5. Triglycerides

    Time frame: 1 day from time of presentation

    Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients

  6. Biochemical analysis

    Time frame: 1 day from time of presentation

    Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients

  7. HbA1C%

    Time frame: 1 day from time of presentation

    Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients

Sponsors and collaborators

Lead sponsor

Royal College of Surgeons in Ireland - Medical University of Bahrain

Other

Collaborators

  • King Hamad University Hospital, Bahrain

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Oct 22, 2024
Registry last updated
Oct 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.